Scholarlink

Background <p>Lung cancer is the leading cause of cancer-related mortality among various types of cancer. In this way, unfortunately, some conventional modalities in cancer treatment such as surgery, immunotherapy, chemotherapy, etc., have high levels of deficiencies and even they can lead to death. To solve this challenge, this paper aims to develop a novel technology such as drug delivery systems (DDSs) based on nanoparticles (NPs).</p> Methods <p>To do so, chitosan (CS)-polycaprolactone (PCL) NPs were fabricated for efficient silver (Ag) NPs and sodium butyrate (NB) delivery to A549 lung cancer cells. Then, the CS-PCL-Ag-NB sample was characterized using FT-IR, DLS, TEM, and TGA devices. The quality of the syntheses verified, the size determined at about 100&#xa0;nm to 20&#xa0;nm in diameter, high thermal stability determined, and 30% Ag and 8% NB contents were measured for CS-PCL-Ag-NB.</p> Results <p>According to the obtained results, the controlled (eight folds slower compared with pure NB) and pH-sensitive (3 folds faster in pH 5.0) NB releases were observed for nanocarrier. Moreover, the cell viability assay demonstrated more than 75% cytotoxicity for CS-PCL-Ag-NB after 24&#xa0;h treatment with 20 nM concentration. Furthermore, qRT-PCR technique exhibited a 9.6, 5.9, and 7.8 folds increase in the expression levels of Caspase9, Bax, and P53 apoptotic genes after treatment with CS-PCL-Ag-NB.</p> Conclusion <p>High biocompatibility obtained for CS and CS-PCL samples. CS-PCL-Ag-NB indicated higher cancer cell inhibition potency compared with pure NB while fabricated nanocarrier had very low toxicity on MSC normal cells. Finally, the obtained results confirmed the ability of CS-PCL-Ag-NB in suppressing cancer cells and inducing apoptosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lung cancer therapy using a chitosan-based nano drug discovery system of silver nanoparticles and chemotherapeutics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Ghufran Abdulal Shaheed Kemawy,
  • Javad Mohammadnejad,
  • Asghar Narmani,
  • Mehrab Pourmadadi,
  • Hanieh Jafari,
  • Yusuf Döğüş,
  • Sevinc Jafarova Haqverdi,
  • Gülüzar Özbolat,
  • Amin Daemi

摘要

Background

Lung cancer is the leading cause of cancer-related mortality among various types of cancer. In this way, unfortunately, some conventional modalities in cancer treatment such as surgery, immunotherapy, chemotherapy, etc., have high levels of deficiencies and even they can lead to death. To solve this challenge, this paper aims to develop a novel technology such as drug delivery systems (DDSs) based on nanoparticles (NPs).

Methods

To do so, chitosan (CS)-polycaprolactone (PCL) NPs were fabricated for efficient silver (Ag) NPs and sodium butyrate (NB) delivery to A549 lung cancer cells. Then, the CS-PCL-Ag-NB sample was characterized using FT-IR, DLS, TEM, and TGA devices. The quality of the syntheses verified, the size determined at about 100 nm to 20 nm in diameter, high thermal stability determined, and 30% Ag and 8% NB contents were measured for CS-PCL-Ag-NB.

Results

According to the obtained results, the controlled (eight folds slower compared with pure NB) and pH-sensitive (3 folds faster in pH 5.0) NB releases were observed for nanocarrier. Moreover, the cell viability assay demonstrated more than 75% cytotoxicity for CS-PCL-Ag-NB after 24 h treatment with 20 nM concentration. Furthermore, qRT-PCR technique exhibited a 9.6, 5.9, and 7.8 folds increase in the expression levels of Caspase9, Bax, and P53 apoptotic genes after treatment with CS-PCL-Ag-NB.

Conclusion

High biocompatibility obtained for CS and CS-PCL samples. CS-PCL-Ag-NB indicated higher cancer cell inhibition potency compared with pure NB while fabricated nanocarrier had very low toxicity on MSC normal cells. Finally, the obtained results confirmed the ability of CS-PCL-Ag-NB in suppressing cancer cells and inducing apoptosis.